Manufacturers report positive data for the long term efficacy of baricitinib in eczema

In the phase III BREEZE-AD3 trial, after 86 weeks treatment, 40% taking 4 mg were assessed as full or partial responders (clear or almost clear skin) from a baseline of 45.7% at study entry. Participants for this extension trial came from a 16 week originating study.

Source:

PharmaTimes